Session » Spondylarthropathies Psoriatic Arthritis - Pathogenesis, Etiology

Date: Sunday, November 8, 2015

Time: 2:30PM-4:00PM

Meeting: 2015 ACR/ARHP Annual Meeting

Abstract Number: 979

HLA Class I Genes As Susceptibility Markers of Psoriatic Arthritis in Patients with Psoriasis – a Meta-Analysis

Abstract Number: 980

Association of Platelet Endothelial Cell Adhesion Molecule-1 and ß1 Integrin Gene Polymorphisms with Uveitis Development in Ankylosing Spondylitis

Abstract Number: 981

Anti-IL-17A Treatment Blocks Inflammation, Destruction and New Bone Formation in Experimental Spondyloarthritis in HLA-B27 Transgenic Rats

Abstract Number: 982

CD4+CD146+ T Cells: The Primed IL-17 Secreting Cells in the Pathogenesis of Psoriatic Arthritis

Abstract Number: 983

ERAP1 Deficiency Protects HLA-B27 Transgenic Rats from Arthritis

Abstract Number: 984

Tofacitinib Inhibits Inflammation and New Bone Formation in Murine Spondyloarthritis but Does Not Adversely Inhibit Normal Human MSC Function

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.